TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00792337
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg per oral once daily for 8 weeks
Study: NCT00792337
Drug: B1-6-12
Normalized name: vitamin B1 12.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 table per day for 8 weeks
Study: NCT02824419
Drug: Methionine
Normalized name: Methionine
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject undergoes imaging studies with FDG and with methionine.
Study: NCT00294918
Drug: Serostim®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.
Study: NCT03751566
Drug: Standard supportive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard supportive therapy
Study: NCT00398554
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m2 i.v. 60 Min.-Inf. day 1 and 21
Study: NCT00398554
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/m²/day, 2 hours i.v.infusion on day 21
Study: NCT00290563
Drug: MK0594
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03662893
Drug: Antimuscarinic drugs used in overactive bladder
Normalized name: Sus scrofa urinary bladder preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimuscarinic drugs (Tolterodine, solifenacin, propiverine, darifenacin,fesoterodine)
Study: NCT00159510
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An inhalation of NO via ETT at 10 ppm, partially weaned by 72 hrs of therapy
Study: NCT00159510
Drug: Methylene blue & nitric oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: See the dosage in the previous arms
Study: NCT00690560
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02567773
Drug: GSK2881078
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2881078 hot melt solutions, ranging in concentration from 0.05 mg/g to 50 mg/g, will be prepared by weighing drug substance directly into specific quantities of the hot melt vehicle solution. Subjects will be administered GSK2881078 (dose for Cohort 1: 0.75 mg for females and 1.5 mg for males) hot melt solution within capsule orally with water.
Study: NCT02567773
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered as hot melt vehicle placebo within capsule orally with water.
Study: NCT01096277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, one per day for two weeks
Study: NCT01954589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00578461
Drug: Ara C
Normalized name: Toxocara cati Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 mg/m\^2 - pts will recieve via IV every 12 hours for 6 doses starting at 20:00 hours on day -8
Study: NCT00578461
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 45 mg/kg; IV once daily on day -7 and day -6 starting at 1400 hours
Study: NCT00412061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 10-mg oral daily dosing regimen (two 5-mg tablets) of matching placebo.
Study: NCT01326754
Drug: Artemether-lumefantrine combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible formulation of artemether-lumefantrine at a dose of 2/12 mg/kg body weight of artemether and lumefantrine, respectively, per dose, given twice a day for 3 days
Study: NCT01418339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole-matching placebo tablet administered orally once a week.
Study: NCT00885495
Drug: darunavir, ritonavir, rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir 600 mg twice daily for 7 days ritonavir 100 mg twice daily for 7 days rosuvastatin 10 mg once daily for 7 days Combination of all three drugs for 7 days
Study: NCT01839643
Drug: Meloxicam 2.4 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g in Vaginal Ring
Study: NCT02093143
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target-controlled infusion of remifentanil 50 µg/ml using the pharmacologic model of Minto et al. to achieve a theorical brain concentration of 1.5 ng/ml.
Study: NCT04565379
Drug: NuSepin® 0.1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: NuSepin® 0.1 mg
Study: NCT04565379
Drug: NuSepin® 0.2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: NuSepin® 0.2 mg
Study: NCT04565379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT03334136
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five capsules the first day and thereafter one capsule every week for 4 months.
Study: NCT01305824
Drug: PRT-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT-201 10 micrograms administered at the time of AVF creation.
Study: NCT01305824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at the time of AVF creation.
Study: NCT01305824
Drug: PRT-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT-201 30 micrograms administered at the time of AVF creation.
Study: NCT02031744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg intravenous administration every 3 weeks
Study: NCT02842827
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration
Study: NCT03241303
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets on experimental day.
Study: NCT03241303
Drug: Placebo Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg/ml placebo saline infusion on experimental day.
Study: NCT00004658
Drug: thymidine
Normalized name: Thymidine
DrugBank: Thymidine (DB04485)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004658
Drug: uridine
Normalized name: Uridine
DrugBank: Uridine (DB02745)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00225875
Drug: Mabthéra
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00825825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two weeks of placebo taken orally.
Study: NCT01981772
Drug: 4% lidocaine with 1:100,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: see arm/group description
Study: NCT01981772
Drug: 4% buffered lidocaine with 1:100,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: see arm/group description
Study: NCT01090037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01513967
Drug: RPh201, botanical drug product
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC administration at varying doses
Study: NCT01513967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC administration at varying doses
Study: NCT00004125
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02719197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching AC-083 capsules
Study: NCT00008047
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004125
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02048358
Drug: 2B3-201
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02436824
Drug: AB001 patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two AB001 patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
Study: NCT00216255
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02048358
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01930240
Drug: TRIA-662
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-MNA Chloride
Study: NCT01930240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind placebo
Study: NCT04019561
Drug: Placebo for MEDI0382 high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for MEDI0382 high dose administered subcutaneously
Study: NCT04019561
Drug: Placebo for MEDI0382 low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for MEDI0382 low dose administered subcutaneously
Study: NCT01593735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, orally, once daily for 7 days
Study: NCT02054520
Drug: HyperAcute®-Melanoma (HAM) Immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00349674
Drug: Azathioprine: 2 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00349674
Drug: methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03616977
Drug: LY900014 U-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04164446
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo that will be used contains starch and glucose.
Study: NCT01856556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV or PO placebo administration
Study: NCT03427086
Drug: Biotin
Normalized name: Biotin
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High dose biotin
Study: NCT03427086
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet similar in shape and size to the biotin tablet
Study: NCT01959477
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03174795
Drug: RO7079901
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive RO7079901 2000 milligrams (mg) IV treatment, three times a day (TID) for up to 14 days.
Study: NCT01125774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match telcagepant 140 mg film coated tablet for oral administration
Study: NCT03202875
Drug: SAR341402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT00994682
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral tablet identical to pioglitazone will be given once daily but without active drug for 18 months.
Study: NCT02355704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure were performed
Study: NCT00928018
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously on the first, third and sixth day after transplant
Study: NCT00744081
Drug: AraC
Normalized name: Carac
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01205100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02784652
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid: every 4 weeks, 6 times, 4.0 mg iv
Study: NCT03256981
Drug: TKI
Normalized name: Catkin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued background TKI alone
Study: NCT00974376
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200mg/day of placebo for 12 weeks
Study: NCT00231946
Drug: VP4896
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01615991
Drug: Radiosynoviorthesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular administration from 111 to 222 Mbq yttrium-90 per joint
Study: NCT01049932
Drug: TMC278LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC278LA 600mg injected intramuscularly (i/m)
Study: NCT02447172
Drug: Gentamicin Collagen sponge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
Study: NCT00705861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as a substitute of SK3530 100mg
Study: NCT02116868
Drug: Tailored remifentanil controlled infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed
Study: NCT02731573
Drug: D-PLEX
Normalized name: Kleer Plex
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.
Study: NCT03226444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop (approximately 50 microliters) of placebo solution will be administered three times a day (TID) to both eyes for four weeks.
Study: NCT04412291
Drug: Standard-of-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2\>93%. Thrombosis prophylaxis (Fragmin or Innohep and Klexane® or new oral anticoagulants including dabigatran, apixaban or rivaroxaban).~Steroids (Betapred 6 mg po) Broad spectrum antibiotics (only in arm B and C)
Study: NCT02866539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar looking inactive powder
Study: NCT02533570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01455857
Drug: ITCA 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 is exenatide in DUROS
Study: NCT01937156
Drug: SP-01 (Granisetron Transdermal Delivery System)
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP-01 will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days.
Study: NCT01905137
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00408252
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: no intervention
Study: NCT03946657
Drug: Inhalational anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen/air (fraction of inspired oxygen (FiO2) of 0.40), inspiratory fresh gas flow of 2 L/min), sevoflurane (1 minimum alveolar concentration \[MAC\]) and remifentanil IV infusion (0.1-0.25 mcg/kg of LBW/min) were used.Neuromuscular blockade was performed during the operation by rocuronium infusion (0.3-0.7 mg/kg of LBW/h), ensuring that PTC was zero.
Study: NCT00758277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar Pill
Study: NCT03946657
Drug: Intravenous anesthetic
Normalized name: Intravenous anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol infusion (4-8 mg/kg of total body weight/h), oxygen/air (FiO2 of 0.40; inspiratory fresh gas flow of 2 L/min) and remifentanil IV infusion (0.1-0.25 μg/kg of LBW/min) were used.Neuromuscular blockade was performed during the operation by rocuronium infusion (0.3-0.7 mg/kg of LBW/h), ensuring that PTC was zero.
Study: NCT01324596
Drug: Intravenous
Normalized name: INTRAVENOUS SETS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoimmunotheraphy
Study: NCT03705832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT04241601
Drug: Interleukin-2 [IL-2]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator: IL-2 plays a key role in Treg cell development, expansion, survival and suppressive function
Study: NCT01880528
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00750802
Drug: AZD6280
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg Capsule, oral, single-dose
Study: NCT00750802
Drug: AZD6280
DrugBank: AZD-6280 (DB12210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg Capsule, oral, single-dose
Study: NCT00750802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00918983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intraprostatic injection of placebo
Study: NCT01122160
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with berries (blackberries + strawberries)
Study: NCT02721173
Drug: Adapalene 0.1% gel plus clindamycin 1% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and adapalene will be applied 5-10 minutes later.
Study: NCT06081699
Drug: TNP-2198 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo for TNP-2198 active drug
Study: NCT00038766
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo IV
Study: NCT00904046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken orally once a day for 6 months.
Study: NCT04058366
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) tablet for oral administration.
Study: NCT01974687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to uprifosbuvir capsule administered by mouth.
Study: NCT00972985
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, single acute dose
Study: NCT04124822
Drug: Piroxicam 20 mg
Normalized name: piroxicam 20 MG
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicm is from oxicam family of anti inflammatory drug that inhibits prostaglandin synthesis and effectively lower pain threshold levels
Study: NCT04124822
Drug: prednisolone 20 mg
Normalized name: prednisolone 20 MG
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisolone is from steroid family of anti inflammatory drug that inhibit arachidonic acid and effectively lowers the pain
Study: NCT00626678
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: It is given in a consistent dosage of 2.5 mg/kg/day throughout the study
Study: NCT00626678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given in place of Azathioprine 2.5 mg/kg/day throughout the study
Study: NCT01497600
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
Study: NCT00545051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po monthly for 12 months
Study: NCT00545051
Drug: ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg po monthly for 12 months
Study: NCT03094897
Drug: 18F-Al-NOTA-MATBBN PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-Al-NOTA-MATBBN(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
Study: NCT00480376
Drug: gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02590133
Drug: Fluorouracil (5-Fu)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
Study: NCT01039090
Drug: Usual dopaminergic per os treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific change in the dopaminergic per os treatment
Study: NCT02187211
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02187211
Drug: Placebo (for Minocycline)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03568331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT00079989
Drug: tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04342793
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04342793
Drug: ALS-L1023 1,200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALS-L1023
Study: NCT04342793
Drug: ALS-L1023 1,800mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALS-L1023
Study: NCT02183051
Drug: Meloxicam 7.5 mg
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183051
Drug: Meloxicam 1.875 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183051
Drug: Ibuprofen 200 mg
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02183051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183051
Drug: Meloxicam 15 mg
Normalized name: meloxicam 15 MG
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02183051
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00407576
Drug: [11C]MeS-IMPY
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01944371
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.
Study: NCT00069108
Drug: 5 FU
Normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed, in 2 week cycles